BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 1906017)

  • 41. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
    Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
    Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
    Hemrika DJ; Slaats EH; Schoemaker J
    Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception.
    Subakir SB; Hadisaputra W; Siregar B; Irawati D; Santoso DI; Cornain S; Affandi B
    Hum Reprod; 1995 Oct; 10(10):2579-83. PubMed ID: 8567774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subdermal contraceptive implants.
    Peralta O; Diaz S; Croxatto H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamic testing of hypothalamic-pituitary function in abnormalities of ovulation.
    Jones GE; Wentz AC; Rosenwaks Z; Shoemaker J
    Am J Obstet Gynecol; 1977 Dec; 129(7):760-76. PubMed ID: 343592
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
    Landgren BM; Johannisson E; Masironi B; Diczfalusy E
    Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods.
    Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E
    Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
    Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of enlarged ovarian follicles among users of levonorgestrel subdermal contraceptive implants (Norplant).
    Alvarez-Sanchez F; Brache V; de Oca VM; Cochon L; Faúndes A
    Am J Obstet Gynecol; 2000 Mar; 182(3):535-9. PubMed ID: 10739504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Timing of onset of contraceptive effectiveness in Norplant implant users. II. Effect on the ovarian function in the first cycle of use.
    Brache V; Blumenthal PD; Alvarez F; Dunson TR; Cochon L; Faundes A
    Contraception; 1999 Apr; 59(4):245-51. PubMed ID: 10457869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of a once weekly oral contraceptive upon gonadotrophin and gonadal steroid levels.
    Tredway DR; Mishell DR
    Contraception; 1974 Aug; 10(2):159-69. PubMed ID: 4418460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovulation inhibition by a new low-dose progestagen.
    Viinikka L; Hirvonen E; Ylikorkala O; Nummi S; Virkkunen P; Ranta T; Alapiessa U; Vihko R
    Contraception; 1977 Jul; 16(1):51-8. PubMed ID: 334460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
    Nuttall ID; Elstein M; Fahmy DR
    Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission.
    Morris SE; Groom GV; Cameron ED; Buckingham MS; Everitt JM; Elstein M
    Contraception; 1979 Jul; 20(1):61-9. PubMed ID: 477318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.